Unither Pharmaceuticals
Unither Pharmaceuticals specialises in the development and manufacturing of single-dose liquid formulations, including eye drops, saline solutions and asthma medications in BFS single doses and liquid stick-packs, for originator pharma, and generics companies.
Headquarters
Unither Pharmaceuticals SAS
3-5 rue Saint-Georges
75009 Paris
France
Unither Pharmaceuticals is a pharmaceutical subcontractor specialising in the development and manufacturing of single-dose liquid formulations, including eye drops, saline solutions and asthma medications in BFS single doses and liquid stick-packs, for originator pharmaceutical companies and generics manufacturers.
Its technologies include:
- Blow-fill-seal (BFS) technology for sterile unit-doses
- Liquid liquid Stick-Pack technology
- Powder powder Stick-Pack technology
- Effervescent improved dry formulations
- Patented drug delivery systems for per-buccal mucous administration
Employing more than 2,000 people in eight manufacturing plants in France, the US, Brazil and China, Unither Pharmaceuticals recorded sales of €371 million (£318 million) in 2022. It has developed and manufactured products sold in over 100 countries and has partnered with numerous pharmaceutical companies.
Unither was founded in 1993, and is owned privately, including by management and private equity companies (such as Keensight Capital, Paris, France).
Articles by Unither Pharmaceuticals
